Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reach...

Full description

Bibliographic Details
Main Authors: Marie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, Virginia Castillo Cano, Daniel Massó-Vallés, Laia Foradada Felip, Sergio López-Estévez, Erika Serrano del Pozo, Hugo Thabussot, Laura Soucek
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
protein therapeutics
MYC
Omomyc
mass spectrometry
LC-PRM
Online Access:https://www.mdpi.com/2072-6694/15/3/826

Similar Items

Similar Items